Recurrent Neuroblastoma Completed Phase 2 Trials for Sirolimus (DB00877)

Also known as: Neuroblastoma Recurrent

IndicationStatusPhase
DBCOND0028756 (Recurrent Neuroblastoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01767194Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaTreatment